vaginal laxity
Conditions
Interventions
Pelvic floor muscle training group:The patients underwent active pelvic floor muscle training with no less than 3s in each contraction, 2-6s relaxation, 15-30min in one group, 3 groups/day, lasting fo
Pelvic floor muscle training and laser group:The patients underwent active pelvic floor muscle training with no less than 3s in each contraction, 2-6s relaxation, 15-30min in one group, 3 groups/day,
and received dot matrix CO2 laser treatment with a 30 day interval between each treatment, 3 times per course.
Pelvic floor muscle training and pelvic floor electrical stimulation combined with biofeedback group:The patients underwent active pelvic floor muscle training with no less than 3s in each contraction
and performed pelvic floor electrical stimulation combined with biofeedback, each treatment was 30min, the electrical stimulation was 20min, the frequency was 10-50Hz, the pulse width was 200-300µs, a
Pelvic floor muscle training, laser and pelvic floor electrical stimulation combined with biofeedback group:The patients underwent active pelvic floor muscle training with no less than 3s in each cont
received dot matrix CO2 laser treatment with a 30 day interval between each treatment, 3 times per course
Sponsors
Women’s Hospital School of Medicine Zhejiang University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)=18years, with a history of sexual life; (2)diagnosed with Guidelines for plastic surgery treatment of vaginal laxity (3)volunteer to participate in clinical research and have signed informed consent
Exclusion criteria
Exclusion criteria: (1)metal foreign bodies in the treatment area or metal implants in the body (such as heart pacemakers, etc.); (2)sexually transmitted diseases, HIV infection, etc; (3)previous pelvic floor electrical stimulation or magnetic stimulation treatment in the past three months, previous vaginal laser or radiofrequency therapy in the past six months; (4)history of vaginal and pelvic floor surgery history; (5)POP-Q staging greater than II degree; (6)genital tract acute inflammation, infection and bleeding; (7)pregnancy and puerperium; (8)history of genital tract precancerous lesions and malignant tumors, serious heart, brain, kidney, immune, blood and other systems and psychiatric neuropsychological diseases; (9)consciousness and communication disorders, which can not cooperate with the experimen; (10)patients who are participating in other clinical studies; (11)patients deemed unsuitable by the researchers to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal laxity scale;vaginal laxity questionnaire, VLQ; sexual satisfaction questionnaire, SSQ; female sexual function index, FSFI; pelvic organ prolapsed- urinary incontinence sexual questionnaire-12, PISQ-12; clinical global impression of improvement, CGI-I;vaginal microecology; | — |
Secondary
| Measure | Time frame |
|---|---|
| POP-Q staging;surface electromyography of pelvic floor muscles;Pelvic floor 3D ultrasound; | — |
Countries
China
Contacts
Public ContactXie Zhenwei
Women’s Hospital School of Medicine Zhejiang University
Outcome results
None listed